Meeting
2018 Gastrointestinal Cancers Symposium
Neoadjuvant therapy outcomes in nonmetastatic pancreatic cancer.
Authors
Jeanette Muniz Kovtun
Beth Israel Deaconess Medical Center, Boston, MA
Jeanette Muniz Kovtun , Konstantin Kovtun , Koenraad Mortele , James Moser , Andrea J. Bullock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 501)
DOI
10.1200/JCO.2018.36.4_suppl.501
Abstract #
501
Poster Bd #
P1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
First Author: Amit Jethanandani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of chemotherapy for patients with unresectable pancreatic cancer concomitant with collagen disease: A multicenter retrospective observational study.
First Author: Hiroyuki Asama
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effect of neoadjuvant therapy pathway (NATP) for pancreatic cancer on overall patient outcomes.
First Author: Dylan Cooper
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar